The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

长期以来，局部进展期直肠癌的标准治疗方式是「术前新辅助治疗 + 直肠癌根治术 + 术后辅助化疗」。虽然新辅助治疗降低了直肠癌的局部复发率，但远处转移率与远期生存时间并未得到改善。近年来，一种全新的治疗方式——全程新辅助治疗（total ...

Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Neoadjuvant chemotherapy for advanced ovarian cancer was initially administered as an alternative treatment for patients not suitable for primary debulking surgery (PDS) because of unresectable ...

Treatment with nivolumab reduced the risk of disease recurrence, progression or death by 42% compared with placebo. The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with ...

The analysis showed an approximate 40% reduction in the risk of disease recurrence or death after surgery among patients who received at least one dose of adjuvant nivolumab following neoadjuvant ...

Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combined with albumin-bound ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

IDEAYA Biosciences (IDYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...